

Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, *miR-150-5p*, inhibits the aggressiveness of lung squamous cell carcinoma cells

TAKAYUKI SUETSUGU^{1*}, KEIICHI KOSHIZUKA^{2*}, NAOHIKO SEKI², KEIKO MIZUNO¹,
ATSUSHI OKATO², TAKAYUKI ARAI², SHUNSUKE MISONO¹, AKIFUMI UCHIDA¹,
TOMOHIRO KUMAMOTO¹ and HIROMASA INOUE¹

¹Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520; ²Department of Functional Genomics, Chiba University Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan

Received September 13, 2017; Accepted November 24, 2017

DOI: 10.3892/ijo.2017.4232

Abstract. In the present study, in order to elucidate the aggressive nature of lung squamous cell carcinoma (LUSQ), we investigated the oncogenic RNA networks regulated by antitumor microRNAs (miRNAs or miRs) in LUSQ cells. The analysis of our original miRNA expression signatures of human cancers revealed that *microRNA-150-5p* (*miR-150-5p*) was downregulated in various types of cancer, indicating that *miR-150-5p* acts as an antitumor miRNA by targeting several oncogenic genes. Thus, the aims of this study were to investigate the antitumor roles of *miR-150-5p* in LUSQ cells and to identify oncogenes regulated by *miR-150-5p* that are involved in the aggressive behavior of LUSQ. The downregulation of *miR-150-5p* was validated in clinical samples of LUSQ and cell lines (SK-MES-1 and EBC-1). The ectopic overexpression of *miR-150-5p* significantly suppressed cancer cell aggressiveness. Comprehensive gene expression analyses revealed that *miR-150-5p* regulated 9 genes in the LUSQ cells. Among these, matrix metalloproteinase 14 (*MMP14*) was found to be a direct target of *miR-150-5p*, as shown by luciferase reporter assay. The knockdown of *MMP14* using siRNA against *MMP14* (*si-MMP14*) significantly inhibited cancer cell migration and invasion. The overexpression of *MMP14* was detected in clinical specimens of LUSQ by immunohistochemistry. On the whole, these findings suggest that the downregulation of

miR-150-5p and the overexpression of *MMP14* may be deeply involved in the pathogenesis of LUSQ.

Introduction

The improvement of the treatment efficacy of lung cancer is an important issue worldwide. In 2012, 1.8 million individuals were diagnosed with lung cancer worldwide, resulting in the death of 1.6 million individuals (1). The majority of lung cancers (approximately 80%) are classified as non-small cell lung cancer (NSCLC). NSCLC is subdivided into four histopathological subtypes as follows: adenocarcinoma (LUAD), squamous cell carcinoma (LUSQ), large cell carcinoma and neuroendocrine cancer (2). The overall survival rate of patients with NSCLC is poor as almost half of patients have metastatic disease at initial diagnosis (3). In patients with adenocarcinoma, the survival rates are markedly improved by treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), inhibitor of anaplastic lymphoma kinase (ALK) and immune check point drugs (4). By contrast, recent targeted molecular therapies have little benefit to the management of patients with LUSQ (5-7). Therefore, in order to improve the prognosis of patients with LUSQ, it is important to analyze the molecular mechanisms of metastatic pathways using the latest genomic approaches.

The human genome sequencing project has shown that a large proportion of non-coding RNAs (ncRNAs) are transcribed (8). The functions of ncRNAs are varied and they can act as effective regulatory molecules in a wide range of biological progresses (9). ncRNAs are categorized into two classes based on their molecular sizes: long ncRNAs (lncRNAs) and small ncRNAs (9). MicroRNAs (miRNAs or miRs) are members of the small ncRNA family. They are typically 19 to 23 nucleotides length, and they regulate the expression of protein-coding RNAs or non-coding RNAs (10). miRNAs possess unique properties, including the ability of a single miRNA species to regulate a vast number of protein-coding or ncRNAs in human cells (10). Thus, aberrantly expressed miRNAs can disrupt systematically regulated RNA networks

Correspondence to: Dr Naohiko Seki, Department of Functional Genomics, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
E-mail: naoseki@faculty.chiba-u.jp

*Contributed equally

Key words: microRNA, lung squamous cell carcinoma, *miR-150-5p*, matrix metalloproteinase 14, antitumor

in cancer cells. In fact, dysregulated miRNAs are deeply involved in the pathogenesis of human cancers (11).

To elucidate the aggressive nature of LUSQ, we previously identified miRNAs that play regulatory roles in this disease (12-16). For example, our previous studies have revealed that the clustered miRNAs, *miR-1* and *miR-133a*, markedly inhibit cancer cell aggressiveness by regulating actin binding protein CORO1C (12). All family members of *miR-29* (*miR-29a*, *miR-29b* and *miR-29c*) act as anti-metastatic miRNAs by targeting lysyl oxidase homolog 2 (*LOXL2*) (13,14). The overexpression of *LOXL2* has been observed in several types of cancer and the knockdown of *LOXL2* interferes with cancer cell aggressiveness (17,18). Moreover, *miR-206* has been shown to inhibit cancer cell malignancies by targeting two pivotal tyrosine kinase receptors, MET and EGFR, in LUSQ (16). These findings provide new knowledge into the novel molecular mechanisms underlying the pathogenesis of LUSQ.

The analysis of miRNA expression signatures of head and neck squamous cell carcinoma (HNSCC) by RNA sequencing revealed that *miR-150-5p* was downregulated in cancer tissues (19). In addition, the downregulation of *miR-150-5p* was detected in cancer signatures derived from prostate cancer and bladder cancer (20,21). However, the functional significance of *miR-150-5p* in LUSQ remains unknown. Thus, in this study, we focused on *miR-150-5p* and investigated its functional significance and the regulatory RNA networks in LUSQ cells.

Materials and methods

Clinical samples and cell lines. In this study, a total of 33 LUSQs and 24 non-cancerous lung specimens apart from the tumors were obtained from patients who underwent lobectomy at Kagoshima University Hospital from 2010 to 2013. The clinicopathological data of the patients with LUSQ (33 LUSQs and 24 non-cancerous lung specimens) are summarized in Table I. Our study was approved by the Institutional Review Board for Clinical Research of Kagoshima University Hospital. Each patient provided written informed consent and approval prior to obtaining the samples.

Two human LUSQ cell lines (SK-MES-1 and EBC-1) were used in this study as previously described (15,16). The cell lines, SK-MES-1 and EBC-1, were obtained from the Japanese Cancer Research Resources Bank (JCRB) and the American Type Culture Collection (Manassas, VA, USA), respectively.

Mature miRNA and small interfering RNA transfection into LUSQ cells. The following RNA species were used in this study: mature miRNAs, Pre-miRTM miRNA Precursors (has-*miR-150-5p*, assay ID: PM 10070; Applied Biosystems, Foster City, CA, USA), negative control miRNA (Applied Biosystems, assay ID: AM 17111), small interfering RNA (Stealth Select RNAi siRNA, Invitrogen, si-*MMP14* P/N: HSS106639 and HSS106640). RNA species were incubated with Lipofectamine RNAiMax reagent (Invitrogen, Carlsbad, CA, USA) and Opti-MEM (Invitrogen) prior to plating. Subsequently, the complex was added to suspended 1×10^5 cells per-well plated in 6-well plates. Mock-transfected cells were transfected only with Lipofectamine RNAiMax reagent and Opti-MEM at plating. The transfection procedures were as previously described (15,16).

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was isolated using Isogen (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. The integrity of the RNA was checked using an RNA 6000 Nano assay kit and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

The procedure for PCR quantification was as previously described (12,15,16). In brief, we first synthesized cDNA from total RNA of each sample using the TaqMan Reverse Transcription kit (P/N N8080234 and 4366596, Applied Biosystems). Subsequently, we evaluated the expression of the gene by TaqMan Real-Time PCR Assays. TaqMan probes and primers for *MMP14* (P/N: Hs1037003_g1; Applied Biosystems) were assay-on-demand gene expression products. Stem-loop RT-PCR for *miR-150-5p* (assay ID: 000473; Applied Biosystems) was used. Human *GUSB* (P/N: Hs99999908_m1; Applied Biosystems) and *RNU48* (assay ID: 001006; Applied Biosystems) were used as normalized controls. All reactions were performed in triplicate and the $\Delta\Delta C_t$ method was employed to calculate the fold change.

Cell proliferation, migration and invasion assays. To investigate the functional significance of *miR-150-5p* or *MMP14* silencing by siRNA knockdown, we performed cell proliferation, migration and invasion assays using the SK-MES-1 and EBC-1 cells.

The cells were transfected with 10 nM miRNA or siRNA by reverse transfection and plated in 96-well plates at 5×10^4 cells per well. After 72 h, cell proliferation was determined by XTT assay using Cell Proliferation kit (Biological Industries, Kibbutz Beit Haemek, Israel).

Cell migration activity was evaluated by wound healing assay. The cells were seeded in 6-well plates at 1×10^5 cells per well. At 48 h after transfection, the cell monolayer was scraped using a P-200 micropipette tip. The initial gap length and residual gap length 24 h after wounding were calculated from photomicrographs.

Cell invasion assay was carried out using modified Boyden chambers, consisting Transwell pre-coated Matrigel membrane filter inserts with 8 μ m pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA). At 48 h after transfection, the cells were planted in the inserts at 1×10^5 per well. At 72 h after transfection, the cells invaded to the lower side were fixed and stained with Diff-Quick (Sysmex Corp., Kobe, Japan). The number of cells invaded to the lower surface was determined microscopically by counting 8 areas of constant size per well. All experiments were performed in triplicate. The procedures of these functional assays were as previously described (15,16).

Western blot analysis. At 72 h after transfection, protein lysates (50 μ g) were separated on NuPAGE on 4-12% Bis-Tris gels (Invitrogen) and transferred onto polyvinylidene fluoride membranes (GE Healthcare Japan, Tokyo, Japan). Immunoblotting was performed with monoclonal MMP14 antibody (1:2,000 dilution) (ab51074; Abcam, Cambridge, UK). GAPDH antibody (1:10,000 dilution) (ab8245; Abcam) was used as an internal control. The membranes were washed and then incubated with an anti-rabbit-IgG, HRP-linked antibody (#7074; Cell Signaling Technology, Danvers, MA, USA). Complexes were visualized with Clarity Western ECL Substrate (Bio-Rad, Hercules, CA, USA). The procedures have been described in our previous studies (15,16).

Table I. Characteristics of lung cancer and non-cancerous cases.

A, Characteristics of the lung cancer cases		
Lung cancer patients	n	(%)
Total number	33	
Median age (range, years)	70 (55-88)	
Sex		
Male	31	93.9
Female	2	6.1
Pathological stage		
IA	5	15.2
IB	9	27.3
IIA	4	12.1
IIB	6	18.2
IIIA	8	24.2
IIIB	1	3.0
B, Characteristics of the non-cancerous cases		
Non-cancerous tissues	n	
Total number	24	
Median age (range, years)	69 (50-88)	
Sex		
Male	24	
Female	0	

Identification of miR-150-5p target oncogenic genes in LUSQ cells. Specific genes regulated by *miR-150-5p* were identified by a combination of *in silico* and comprehensive gene expression analyses. Our target search strategies were described as previously (15,16). First, we selected putative *miR-150-5p* target genes using the TargetScan 7.1 database (http://www.targetscan.org/vert_71/). We then performed comprehensive gene analysis of downregulated genes in *miR-150-5p* transfected EBC-1 cells and upregulated genes in NSCLC from GEO database. The microarray data were deposited into GEO (<http://www.ncbi.nlm.nih.gov/geo/>), with the Accession number: GSE82108. Upregulated genes in NSCLC clinical specimens were obtained from the GEO database (Accession number: GSE19188).

Plasmid construction and dual-luciferase reporter assays. The wild-type or deletion-type sequences of the 3'-untranslated region (UTR) of *MMP14* in *miR-150-5p* target sites were inserted in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). We used 3 sequences that were putative *miR-150-5p* target sites of *MMP14* by the TargetScan database (position 567-573: UUGGGAG; position 804-810: UGGGAGA and position 1381-1388: UUGGGAGA). The procedure for dual luciferase reporter assays was as previously described (15,16). The synthesized DNA was cloned into the psiCHECK-2 vector. EBC-1 cells were transfected with the vector, miRNAs and Lipofectamine 2000 in Opti-MEM (both from Invitrogen). The activities of Firefly and *Renilla* luciferases in cell lysates

Table II. Immunohistochemistry status and characteristics of the lung cancer and non-cancerous cases.

A, Immunohistochemical status and characteristics of the LUSQ cases						
Patient no.	Grade	T	N	M	Pathological stage	Immunohistochemical staining intensity
1	1	3	1	0	IIIA	(+)
2	1	3	0	0	IIIA	(++)
3	2	2	1	0	II	(+++)
4	2	3	0	0	IIIA	(++)
5	1	2	0	0	I	(++)
6	1	2	1	0	II	(+++)
7	1	3	1	0	IIIA	(++)
8	1	2	0	0	I	(++)
9	1	2	1	0	II	(++)
10	1	2	0	0	I	(+++)
11	2	2	2	0	IIIA	(++)
12	2	2	0	0	I	(+++)
13	2	1	0	0	I	(+++)
14	2	1	0	0	I	(+++)
15	2	2	1	0	II	(++)
16	2	3	1	0	IIIA	(+++)
17	2	2	0	0	I	(++)
18	2	2	1	0	II	(++)
19	2	3	2	0	IIIA	(+++)
20	2	2	0	0	I	(++)
B, Immunohistochemical status of non-cancerous cases						
Patient no.	Immunohistochemical staining intensity					
91	(+)					
92	(+)					
93	(+)					
94	(-)					
95	(+)					
96	(+)					
97	(-)					
98	(++)					
99	(+)					
100	(+)					

B, Immunohistochemical status of non-cancerous cases

Patient no.	Immunohistochemical staining intensity
91	(+)
92	(+)
93	(+)
94	(-)
95	(+)
96	(+)
97	(-)
98	(++)
99	(+)
100	(+)

were determined with a dual-luciferase assay system (E1910; Promega). Normalized data were calculated as the quotient of *Renilla*/Firefly luciferase activities.

Immunohistochemistry staining and scoring. A tissue microarray containing a total of 30 lung samples, 20 LUSQ specimens and 10 normal lung samples was obtained from US Biomax (Derwood, MD, USA; Cat. no. BC04002). The patient characteristics for the tissue microarray are shown in Table II. The TNM classification of cancer tissues was according to the 7th edition of the American Joint Committee on Cancer (22).




Figure 1. Expression levels of *miR-150-5p* in clinical specimens and cell lines and functional assays of *miR-150-5p* in LUSQ cells. (A) Expression levels of *miR-150-5p* in LUSQ clinical specimens and cell lines. *RNU48* was used as an internal control. (B) Cell proliferation was determined by XTT assay 72 h after transfection with *miR-150-5p*; * $P < 0.0001$. (C) Cell movement was assessed by migration assays 72 h after transfection with *miR-150-5p*; * $P < 0.0001$. (D) Characterization of cell invasive capacity 72 h after transfection with *miR-150-5p*; * $P < 0.0001$.

We confirmed the expression status of *MMP14* in the LUSQ clinical specimens using immunohistochemical staining. The procedure for immunohistochemistry was as previously described (16,23,24). The tissue sections were incubated with the primary rabbit monoclonal antibody against *MMP14* (1:5,000 dilution; ab51074; Abcam). The slide was treated with biotinylated goat anti-rabbit antibodies. Diaminobenzidine hydrogen peroxidase was the chromogen and counterstaining was done with 0.5% hematoxylin. Each tissues sample was scored on the basis of the intensity and area of staining. The procedure for score for staining tissues was as previously described (25).

Statistical analysis. Relationships between two or three variables and numerical values were analyzed using Mann-Whitney U tests or Bonferroni-adjusted Mann-Whitney U tests. Expert

StatView software (version 5.0; SAS Institute Inc., Cary, NC, USA) was used for these analyses. Statistical analysis was carried out as previously described (19,23).

Results

Expression levels of *miR-150-5p* in LUSQ clinical specimens and cell lines. The expression levels of *miR-150-5p* were significantly decreased in the cancer tissues compared with non-cancerous tissues ($P < 0.0001$; Fig. 1A). In addition, the expression levels of *miR-150-5p* in the cancer cell lines, SK-MES-1 and EBC-1, were markedly downregulated (Fig. 1A).

Effects of the ectopic overexpression of *miR-150-5p* on cell proliferation, migration and invasion in LUSQ cell lines.

Table III. Putative target genes regulated by *miR-150-5p* in LUSQ cells.

Gene symbol	Gene name	Conserved	Poorly conserved	GEO82108 log ₂ ratio	GEO19188 Fold change
<i>MMP14</i>	Matrix metalloproteinase 14 (membrane-inserted)	1	2	-1.11	1.872
<i>CPD</i>	Carboxypeptidase D	1	0	-1.07	1.071
<i>LRRC58</i>	Leucine rich repeat containing 58	1	6	-1.19	0.733
<i>CDC73</i>	Cell division cycle 73	1	2	-2.16	0.605
<i>ENSA</i>	Endosulfine alpha	1	5	-1.79	0.501
<i>DSEL</i>	Dermatan sulfate epimerase-like	1	0	-1.17	0.487
<i>CSNK1A1</i>	Casein kinase 1, alpha 1	1	1	-1.13	0.292
<i>CHD2</i>	Chromodomain helicase DNA binding protein 2	1	2	-2.14	0.260
<i>CAPZB</i>	Capping protein (actin filament) muscle Z-line, beta	1	4	-1.18	0.201

Selection strategy for identification of
miR-150-5p regulated genes




Figure 2. Flow chart depicting the strategy for identification of *miR-150-5p* target genes. Combined *in silico* database searching and comprehensive gene expression analysis using *miR-150-5p* transfectants of EBC-1 were applied to identify putative *miR-150-5p* target genes. A total of 9 genes were identified as candidate targets of *miR-150-5p* regulation.

To validate the antitumor effects of *miR-150-5p*, we carried out gain-of-function assays by transfecting miRNA into two LUSQ cell lines (SK-MES-1 and EBC-1). Cell proliferation was significantly inhibited in the cells transfected with the mature *miR-150-5p* in comparison with the mock (transfection reagent only)- or miR-control-transfected cells (Fig. 1B). Furthermore, cell migration and invasion activities were markedly reduced in the cells transfected with the *miR-150-5p* expression plasmid compared to the mock- or miR-control-transfected cells (Fig. 1C and D).

Identification of putative targets of *miR-150-5p* regulation in LUSQ cells. Our strategy for the selection of *miR-150-5p* target oncogenic genes is shown in Fig. 2. First, we selected putative *miR-150-5p* target genes using the TargetScan 7.1 database and

identified 351 genes. We then performed comprehensive gene expression analysis using *miR-150-5p* transfectants of EBC-1 cells, with negative control miRNA transfectants serving as controls (Accession number: GSE 82108). In this assessment, 15 genes were commonly downregulated (log₂ ratio < -1.0). The gene set was then analyzed with a publicly available gene expression data set in GEO (Accession number: GSE 19188) and genes upregulated in LUSQ were selected (fold change > 0). A total of 9 genes were identified as candidate targets of *miR-150-5p* regulation (Table III).

Among these candidate genes, we focused on *MMP14* as the aberrant expression of the matrix metalloproteinase family enhances cancer cell migration and invasion (26). The ectopic overexpression of *miR-150-5p* significantly inhibited cancer cell migration and invasion in the LUSQ cells (Fig. 1C and D).

Direct regulation of *MMP14* by *miR-150-5p* in LUSQ cells. We investigated whether transfection of the LUSQ cell lines with the *miR-150-5p* expression plasmid would reduce the expression of *MMP14*/MMP14. The mRNA expression levels of *MMP14* were decreased by transfection with the *miR-150-5p* expression plasmid compared with the mock- or miR-control-transfected cells (Fig. 3A). Furthermore, the protein expression levels of MMP14 were also decreased by the overexpression of *miR-150-5p* compared with the mock- or miR-control-transfected cells (Fig. 3B).

We also performed luciferase reporter assays with a vector that included the 3'-UTR of *MMP14* to confirm that *miR-150-5p* directly regulated *MMP14* in a sequence-dependent manner. We used vectors encoding the partial wild-type or deletion-type sequences of the 3'-UTR of the *MMP14* with *miR-150-5p* target sites. Three binding sites for *miR-150-5p* in the 3'-UTR of *MMP14* (positions 567-573, 804-810 and 1381-1388) were predicted by the TargetScan Human database (Fig. 3C). We observed that the luminescence intensities of the proteins coded by vectors carrying the wild-type sequences (positions 804-810 and 1381-1388) were significantly reduced by co-transfection with *miR-150-5p* (Fig. 3C). By contrast, transfection with the deletion-type vector blocked the reduction of luminescence intensities (Fig. 3C). These findings indicated that *miR-150-5p* directly bound to specific two sites in the 3'-UTR of *MMP14*.




Figure 3. Direct regulation of *MMP14* by *miR-150-5p* in LUSQ cells. (A) Expression levels of *MMP14* mRNAs 72 h after transfection of cell lines with 10 nM *miR-150-5p*. *GUSB* was used as an internal control; * $P < 0.0001$. (B) Protein expression of *MMP14* at 72 h after transfection with *miR-150-5p*. GAPDH was used as a loading control. (C) *miR-150-5p* binding sites in the 3'-UTR of *MMP14* mRNA. Dual luciferase reporter assays using vectors encoding putative *miR-150-5p* target sites of the *MMP14* 3'-UTR (positions 567-573, 804-810 and 1381-1388) for wild-type and deletion type. Normalized data were calculated as ratios of *Renilla*/Firefly luciferase activities; * $P < 0.0001$.

Effects of knockdown of MMP14 on the proliferation, migration and invasion of LUSQ cell lines. Loss-of-function assays using siRNA were performed to examine the function of *MMP14* in LUSQ cell lines (SK-MES-1 and EBC-1). The mRNA and protein expression levels of *MMP14* were decreased by transfection with si-*MMP14* in the LUSQ cell lines (Fig. 4A and B).

We then investigated the effects of *MMP14* knockdown on the proliferation, migration, and invasion of LUSQ cell lines. Cancer cell proliferation was significantly reduced in the si-*MMP14*-transfected cells (Fig. 4C). In addition, the migration and invasion activities were significantly attenuated in the si-*MMP14*-transfected cells (Fig. 4D and E).

Expression of MMP14 in LUSQ clinical specimens. We examined the protein expression levels of *MMP14* in LUSQ clinical specimens by immunostaining. We confirmed the

overexpression of *MMP14* in LUSQ lesions compared with that in normal tissues (Fig. 5).

Identification of *MMP14*-regulated genes in LUSQ cells.

To investigate downstream genes regulated by *MMP14*, we performed genome-wide gene expression analysis using si-*MMP14* in EBC-1 cells. A total of 92 genes were identified as *MMP14*-regulated genes (Table IV).

Discussion

Recently, several treatment options have been approved for post-first-line therapy for LUSQ, such as chemotherapy with or without an angiogenesis inhibitor (27), or immunotherapy (4). However, treatment outcomes do not appear to have improved. Therefore, clinicians need new treatment options in their




Figure 4. Knockdown of *MMP14* by siRNA transfection and the response of LUSQ cells. (A) *MMP14* mRNA expression at 72 h after transfection of 10 nM siRNA into LUSQ cells. *GUSB* was used as an internal control; * $P < 0.0001$. (B) *MMP14* protein expression 72 h after transfection with siRNA. GAPDH was used as a loading control. (C) Cell proliferation was determined by XTT assay at 72 h after transfection with siRNA; * $P < 0.0001$. (D) Cell movement was assessed by migration assay 72 h after transfection with siRNA; * $P < 0.0001$. (E) Characterization of invasion at 72 h after transfection with siRNA; * $P < 0.0001$.

approach to LUSQ. Presumably, they should be based on the latest molecular analyses of the pathology of this disease.

In this study, we demonstrated that the restoration of *miR-150-5p* significantly attenuated with cancer cell aggressiveness, suggesting that this miRNA possesses antitumor activity in LUSQ cells. It has been demonstrated that *miR-150-5p* has multiple functions, possessing antitumor activity or oncogenic functions (28). The overexpression of *miR-150-5p* has been reported in several types of cancer (29,30). In contrast to the overexpression of *miR-150-5p* in cancer cells, the antitumor roles of *miR-150-5p* have been reported in several types of cancer through its targeting of oncogenic genes (19,31,32).

Previous studies showed that contradiction resulted as to the expression pattern of *miR-150-5p* in lung cancer (28). Our preliminary data demonstrated that the expression levels of *miR-150-5p* were reduced in lung adenocarcinoma clinical specimens (data not shown). One such study showed that *miR-150-5p* expression was significantly reduced in HNSCC tissues and had antitumor roles. A low expression of *miR-150-5p* has been shown to be significantly associated with a poor prognosis of patients with HNSCC (19). Moreover, integrin subunit alpha 3 (*ITGA3*), integrin subunit alpha 6 (*ITGA6*) and tenascin C (*TNC*) have been identified as oncogenes in HNSCC that were downregulated by *miR-150-5p* (19).

Table IV. Downstream genes regulated by *MMP14* in LUSQ cells.

Gene symbol	Gene name	Expression log ₂ ratio		
		si- <i>MMP14</i> -1	si- <i>MMP14</i> -2	Average
<i>MMP14</i>	Matrix metalloproteinase 14 (membrane-inserted)	-4.19	-3.72	-3.96
<i>LMNB1</i>	Lamin B1	-3.70	-2.97	-3.34
<i>TMEM192</i>	Transmembrane protein 192	-2.61	-3.48	-3.05
<i>MKI67</i>	Marker of proliferation Ki-67	-2.17	-3.85	-3.01
<i>ENPP1</i>	Ectonucleotide pyrophosphatase/phosphodiesterase 1	-2.77	-3.11	-2.94
<i>LPL</i>	Lipoprotein lipase	-2.81	-3.05	-2.93
<i>SLC7A11-AS1</i>	SLC7A11 antisense RNA 1	-3.90	-1.90	-2.90
<i>CDRT1</i>	CMT1A duplicated region transcript 1	-3.92	-1.77	-2.85
<i>FAM129A</i>	Family with sequence similarity 129, member A	-3.68	-1.97	-2.83
<i>BZW1</i>	Basic leucine zipper and W2 domains 1	-3.08	-2.58	-2.83
<i>LYRM1</i>	LYR motif containing 1	-2.63	-2.90	-2.76
<i>CHRNA5</i>	Cholinergic receptor, nicotinic, alpha 5 (neuronal)	-3.31	-2.20	-2.75
<i>MARCH5</i>	Membrane-associated ring finger (C3HC4) 5	-2.23	-3.23	-2.73
<i>DEPDC1</i>	DEP domain containing 1	-3.34	-2.06	-2.70
<i>CBX3</i>	Chromobox homolog 3	-3.06	-2.27	-2.66
<i>ANKRD22</i>	Ankyrin repeat domain 22	-1.50	-3.76	-2.63
<i>JKAMP</i>	JNK1/MAPK8-associated membrane protein	-1.66	-3.37	-2.51
<i>ANTXR1</i>	Anthrax toxin receptor 1	-2.39	-2.59	-2.49
<i>SMAD1-AS1</i>	SMAD1 antisense RNA 1	-2.29	-2.69	-2.49
<i>ATP5E</i>	ATP synthase, H ⁺ transporting, mitochondrial F1 complex, epsilon subunit	-2.31	-2.64	-2.47
<i>TOMM20</i>	Translocase of outer mitochondrial membrane 20 homolog (yeast)	-2.40	-2.41	-2.40
<i>DEFB4A</i>	Defensin, beta 4A	-2.62	-2.12	-2.37
<i>ALDH7A1</i>	Aldehyde dehydrogenase 7 family, member A1	-2.48	-2.25	-2.37
<i>OSBPL8</i>	Oxysterol binding protein-like 8	-2.70	-1.99	-2.34
<i>GLYCTK</i>	Glycerate kinase	-2.58	-2.08	-2.33
<i>SLC16A1</i>	Solute carrier family 16 (monocarboxylate transporter), member 1	-2.82	-1.82	-2.32
<i>C5</i>	Complement component 5	-2.18	-2.42	-2.30
<i>ASNS</i>	Asparagine synthetase (glutamine-hydrolyzing)	-3.09	-1.50	-2.29
<i>POLE2</i>	Polymerase (DNA directed), epsilon 2, accessory subunit	-1.53	-3.05	-2.29
<i>SASS6</i>	Spindle assembly 6 homolog (<i>C. elegans</i>)	-1.94	-2.62	-2.28
<i>SMARCA2</i>	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2	-1.81	-2.68	-2.24
<i>FANCD2</i>	Fanconi anemia, complementation group D2	-2.19	-2.27	-2.23
<i>TMEM154</i>	Transmembrane protein 154	-2.69	-1.77	-2.23
<i>ARHGAP9</i>	Rho GTPase activating protein 9	-2.73	-1.73	-2.23
<i>SPATA5</i>	Spermatogenesis associated 5	-2.64	-1.68	-2.16
<i>ARHGAP11A</i>	Rho GTPase activating protein 11A	-1.71	-2.59	-2.15
<i>OSBPL8</i>	Oxysterol binding protein-like 8	-2.12	-2.16	-2.14
<i>SUV39H2</i>	Suppressor of variegation 3-9 homolog 2 (<i>Drosophila</i>)	-1.77	-2.50	-2.13
<i>ACTL8</i>	Actin-like 8	-2.36	-1.85	-2.10
<i>ESCO2</i>	Establishment of sister chromatid cohesion N-acetyltransferase 2	-2.52	-1.68	-2.10
<i>RAB1A</i>	RAB1A, member RAS oncogene family	-2.07	-2.13	-2.10
<i>FBXO4</i>	F-box protein 4	-1.76	-2.42	-2.09
<i>MAPK6</i>	Mitogen-activated protein kinase 6	-2.32	-1.86	-2.09
<i>RNF180</i>	Ring finger protein 180	-1.91	-2.25	-2.08
<i>DKFZP434I0714</i>	Uncharacterized protein DKFZP434I0714	-1.77	-2.38	-2.08

Table IV. Continued

Gene symbol	Gene name	Expression log ₂ ratio		
		si-MMP14-1	si-MMP14-2	Average
<i>MTBP</i>	MDM2 binding protein	-1.93	-2.21	-2.07
<i>AIF1L</i>	Allograft inflammatory factor 1-like	-2.44	-1.68	-2.06
<i>MOB3B</i>	MOB kinase activator 3B	-1.57	-2.53	-2.05
<i>CGGBP1</i>	CGG triplet repeat binding protein 1	-1.75	-2.34	-2.04
<i>HIST1H2AI</i>	Histone cluster 1, H2ai	-2.46	-1.62	-2.04
<i>FKBP5</i>	FK506 binding protein 5	-1.79	-2.27	-2.03
<i>NUDT21</i>	Nudix (nucleoside diphosphate linked moiety X)-type motif 21	-1.54	-2.45	-2.00
<i>NEIL3</i>	Nei endonuclease VIII-like 3 (<i>E. coli</i>)	-2.02	-1.90	-1.96
<i>ATG4C</i>	Autophagy-related 4C, cysteine peptidase	-1.64	-2.26	-1.95
<i>ECEL1</i>	Endothelin converting enzyme-like 1	-1.89	-1.95	-1.92
<i>KIF11</i>	Kinesin family member 11	-1.55	-2.25	-1.90
<i>TCF19</i>	Transcription factor 19	-1.64	-2.16	-1.90
<i>ZNF681</i>	Zinc finger protein 681	-2.03	-1.75	-1.89
<i>RRM2</i>	Ribonucleotide reductase M2	-1.66	-2.10	-1.88
<i>PLAC8L1</i>	PLAC8-like 1	-1.55	-2.20	-1.88
<i>IL1B</i>	Interleukin 1, beta	-1.69	-2.05	-1.87
<i>DIS3L</i>	DIS3 like exosome 3'-5' exoribonuclease	-1.81	-1.90	-1.85
<i>CKAP2L</i>	Cytoskeleton associated protein 2-like	-1.66	-2.03	-1.84
<i>RRN3</i>	RRN3 RNA polymerase I transcription factor homolog (<i>S. cerevisiae</i>)	-1.54	-2.15	-1.84
<i>TMEM180</i>	Transmembrane protein 180	-2.12	-1.56	-1.84
<i>HS2ST1</i>	Heparan sulfate 2-O-sulfotransferase 1	-1.57	-2.11	-1.84
<i>ZNF414</i>	Zinc finger protein 414	-1.74	-1.89	-1.82
<i>TMEM194B</i>	Transmembrane protein 194B	-1.69	-1.94	-1.82
<i>STXBP5L</i>	Syntaxin binding protein 5-like	-1.92	-1.71	-1.82
<i>CENPI</i>	Centromere protein I	-1.98	-1.64	-1.81
<i>ERCC6L</i>	excision repair cross-complementation group 6-like	-1.60	-2.02	-1.81
<i>SPC24</i>	SPC24, NDC80 kinetochore complex component	-1.79	-1.83	-1.81
<i>KRTAP10-3</i>	Keratin associated protein 10-3	-1.85	-1.76	-1.80
<i>ID2-AS1</i>	ID2 antisense RNA 1 (head to head)	-1.55	-2.02	-1.78
<i>GATA2-AS1</i>	GATA2 antisense RNA 1	-2.03	-1.53	-1.78
<i>FBF1</i>	Fas (TNFRSF6) binding factor 1	-1.55	-2.01	-1.78
<i>MED1</i>	Mediator complex subunit 1	-1.64	-1.91	-1.78
<i>PLCL2</i>	Phospholipase C-like 2	-2.01	-1.52	-1.77
<i>CDKN3</i>	Cyclin-dependent kinase inhibitor 3	-1.56	-1.92	-1.74
<i>CSF3</i>	Colony stimulating factor 3 (granulocyte)	-1.55	-1.92	-1.73
<i>PLAA</i>	Phospholipase A2-activating protein	-1.53	-1.88	-1.70
<i>MCM6</i>	Minichromosome maintenance complex component 6	-1.81	-1.59	-1.70
<i>TRIM14</i>	Tripartite motif containing 14	-1.64	-1.75	-1.69
<i>TUBA3FP</i>	Tubulin, alpha 3f, pseudogene	-1.66	-1.71	-1.68
<i>OVOS2</i>	Ovostatin 2	-1.76	-1.59	-1.67
<i>NUCKS1</i>	Nuclear casein kinase and cyclin-dependent kinase substrate 1	-1.58	-1.75	-1.67
<i>HOOK1</i>	Hook microtubule-tethering protein 1	-1.62	-1.66	-1.64
<i>ZBTB33</i>	Zinc finger and BTB domain containing 33	-1.72	-1.50	-1.61
<i>GALNT4</i>	Polypeptide N-acetylgalactosaminyltransferase 4	-1.70	-1.53	-1.61
<i>RRM1</i>	Ribonucleotide reductase M1	-1.61	-1.61	-1.61
<i>MDM1</i>	Mdm1 nuclear protein homolog (mouse)	-1.69	-1.53	-1.61
<i>FAM72D</i>	Family with sequence similarity 72, member D	-1.51	-1.66	-1.59




Figure 5. Expression of MMP14 in clinical LUSQ specimens using a tissue microarray. (A-C) Immunohistochemical (IHC) staining of MMP14 in LUSQ specimens. The overexpression of MMP14 was observed in cancer lesions. (D) Expression of MMP14 was negative in normal lung tissue. (E) Comparison of IHC staining of MMP14 in LUSQ tissues using IHC scores. MMP14 expression was significantly higher in cancer tissues than in normal lung tissues.

Previous studies have shown that the aberrant expression of integrin family genes and the activation of integrin-mediated oncogenic signaling promotes cancer cell metastasis and the epithelial-mesenchymal transition (EMT) phenotype (33,34). Other studies have demonstrated that *SPOCK1* is directly regulated by *miR-150-5p* in prostate cancer and esophageal squamous cell carcinoma (31,32). The aberrant expression of *SPOCK1* has been observed in several types of cancer and has been shown to play pivotal roles in cancer cell progression, metastasis and drug resistance (35,36). Of note, the ectopic expression of *SPOCK1* induces EMT in lung cancer (37). These findings suggest that the downregulation of *miR-150-5p* induces several cancer-promoting genes and that its expression is deeply involved in cancer pathogenesis.

In this study, to identify oncogenic genes targeted by *miR-150-5p*, we applied gene expression analysis and *in silico* database searches. A total of 9 genes (*MMP14*, *CPD*, *LRRC58*, *CDC73*, *ENSA*, *DSEL*, *CSNK1A1*, *CHD2* and *CAPZB*) were identified as putative targets of *miR-150-5p* regulation in LUSQ cells. Among these, we focused on *MMP14* as the

matrix metalloproteinase family contributes to cancer cell migration and invasion. Our luciferase reporter assay revealed that *MMP14* was directly regulated by *miR-150-5p* in LUSQ cells. The overexpression of *MMP14* was observed in LUSQ clinical specimens and the knockdown of *MMP14* by siRNA significantly interfered *in vitro* with cancer cell malignancies. These findings indicate that *MMP14* acts as an oncogene regulated by the antitumor *miR-150-5p* in LUSQ cells.

MMP14 belongs to the membrane-type matrix metalloprotease (MT-MMP) family that includes pivotal regulators of cell invasion, growth and survival in normal cells (26). The upregulation of MMP14 has been observed in many types of cancer, and the overexpression of MMP14 has been shown to correlate with a poor prognosis in patients with NSCLC, renal cell carcinoma and breast cancer (38-40). Activated MMP14 cleaves pro-MMP2 and pro-MMP13 and the activated form of MMP2 and MMP13 are involved in cancer pathogenesis (26). A major substrate of MMP14 is type I collagen in ECM components. MMP14 is localized to the leading edge of invadopodia in migrating cells, achieving spatially coordinated matrix

degradation to support invasion (41). MMP14 influences cancer cells and cancer niches (ECM and fibroblast cells). MMP14 is mediated through membrane proteins, e.g., receptor tyrosine kinases (RTK) and integrins, and these events promote cancer cell aggressiveness (42,43). For instance, the interaction of MMP14 and CD44 induces the phosphorylation of the EGF receptor and enhances downstream activation of the MAPK and PI3K signaling pathways (44,45).

Proteolytic enzymes, MMPs or MT-MMPs are tightly controlled by tissue inhibitors of metalloproteases (TIMPs) (26). The expression and activation of MMPs and TIMPs are important to biological processes and essential for tissue homeostasis. Dysregulated MMPs and TIMPs have been implicated in cancer cell progression and metastasis (46). Recent studies have indicated that several downregulated miRNAs caused the aberrant expression of MMP14 in cancer cells (47,48). Our recent studies showed the antitumor functions of *miR-375* and *miR-139-5p/-3p* that targeted *MMP13* and *MMP11*, respectively (49,50). These MMPs were overexpressed in cancer specimens, and the restoration of these miRNAs or knockdown of *MMP13* or *MMP11* inhibited cancer cell migration and invasion (49,50). The identification of antitumor miRNAs that regulate novel LUSQ networks may lead to a better understanding of the aggressiveness of this disease.

Taken together, this study demonstrates *miR-150-5p* acts as an antitumor miRNA by targeting *MMP14* in LUSQ cells. The overexpression of *MMP14* may be enhanced in lung cancer oncogenesis. The exploration of antitumor miRNA-mediated regulatory networks may lead to the development of novel treatment strategies for this disease.

Acknowledgements

This study was supported by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI), 17K16893, 15K10801, 16K19458, and 17K09660.

Competing interests

The authors declare that they have no competing interests.

References

- Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C and Reid ME: The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics. *J Thorac Oncol* 11: 1653-1671, 2016.
- Travis WD: Pathology of lung cancer. *Clin Chest Med* 32: 669-692, 2011.
- Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. *Lancet* 382: 709-719, 2013.
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, *et al*: KEYNOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med* 375: 1823-1833, 2016.
- Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI and Johnson DH: Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. *J Clin Oncol* 27: 1405-1412, 2009.
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, *et al*: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 26: 3543-3551, 2008.
- Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, *et al*: Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial. *Ann Oncol* 28: 270-277, 2017.
- Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, *et al*: Landscape of transcription in human cells. *Nature* 489: 101-108, 2012.
- Beermann J, Piccoli MT, Viereck J and Thum T: Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches. *Physiol Rev* 96: 1297-1325, 2016.
- Bartel DP: MicroRNAs: Target recognition and regulatory functions. *Cell* 136: 215-233, 2009.
- Wiener EA: The role of microRNAs in cancer: No small matter. *Eur J Cancer* 43: 1529-1544, 2007.
- Mataki H, Enokida H, Chiyomaru T, Mizuno K, Matsushita R, Goto Y, Nishikawa R, Higashimoto I, Samukawa T, Nakagawa M, *et al*: Downregulation of the microRNA-1/133a cluster enhances cancer cell migration and invasion in lung-squamous cell carcinoma via regulation of Coronin1C. *J Hum Genet* 60: 53-61, 2015.
- Kamikawaji K, Seki N, Watanabe M, Mataki H, Kumamoto T, Takagi K, Mizuno K and Inoue H: Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis. *J Hum Genet* 61: 985-993, 2016.
- Mizuno K, Seki N, Mataki H, Matsushita R, Kamikawaji K, Kumamoto T, Takagi K, Goto Y, Nishikawa R, Kato M, *et al*: Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma. *Int J Oncol* 48: 450-460, 2016.
- Mataki H, Seki N, Mizuno K, Nohata N, Kamikawaji K, Kumamoto T, Koshizuka K, Goto Y and Inoue H: Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma. *Oncotarget* 7: 72084-72098, 2016.
- Mataki H, Seki N, Chiyomaru T, Enokida H, Goto Y, Kumamoto T, Machida K, Mizuno K, Nakagawa M and Inoue H: Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. *Int J Oncol* 46: 1039-1050, 2015.
- Fukumoto I, Kikkawa N, Matsushita R, Kato M, Kurozumi A, Nishikawa R, Goto Y, Koshizuka K, Hanazawa T, Enokida H, *et al*: Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. *J Hum Genet* 61: 109-118, 2016.
- Kurozumi A, Kato M, Goto Y, Matsushita R, Nishikawa R, Okato A, Fukumoto I, Ichikawa T and Seki N: Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. *Int J Oncol* 48: 1837-1846, 2016.
- Koshizuka K, Nohata N, Hanazawa T, Kikkawa N, Arai T, Okato A, Fukumoto I, Katada K, Okamoto Y and Seki N: Deep sequencing-based microRNA expression signatures in head and neck squamous cell carcinoma: Dual strands of pre-miR-150 as antitumor miRNAs. *Oncotarget* 8: 30288-30304, 2017.
- Goto Y, Kurozumi A, Arai T, Nohata N, Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, *et al*: Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. *Br J Cancer* 117: 409-420, 2017.
- Itesako T, Seki N, Yoshino H, Chiyomaru T, Yamasaki T, Hidaka AH, Yonezawa T, Nohata N, Kinoshita T, Nakagawa M, *et al*: The microRNA expression signature of bladder cancer by deep sequencing: The functional significance of the miR-195/497 cluster. *PLoS One* 9: e84311, 2014.
- Mirsadraee S, Oswal D, Alizadeh Y, Caulo A and van Beek E Jr: The 7th lung cancer TNM classification and staging system: Review of the changes and implications. *World J Radiol* 4: 128-134, 2012.
- Koshizuka K, Hanazawa T, Fukumoto I, Kikkawa N, Matsushita R, Mataki H, Mizuno K, Okamoto Y and Seki N: Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma. *J Hum Genet* 62: 113-121, 2017.

24. Okato A, Goto Y, Kurozumi A, Kato M, Kojima S, Matsushita R, Yonemori M, Miyamoto K, Ichikawa T and Seki N: Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer. *Int J Oncol* 49: 111-122, 2016.
25. Kojima S, Chiyoumaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, *et al*: Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. *Br J Cancer* 106: 405-413, 2012.
26. Turunen SP, Tatti-Bugaeva O and Lehti K: Membrane-type matrix metalloproteases as diverse effectors of cancer progression. *Biochim Biophys Acta* 1864 (11 Pt A): 1974-1988, 2017.
27. Maione P, Sgambato A, Casaluce F, Sacco PC, Santabarbara G, Rossi A and Gridelli C: The role of the antiangiogenic ramucirumab in the treatment of advanced non small cell lung cancer. *Curr Med Chem* 24: 3-13, 2017.
28. Wang F, Ren X and Zhang X: Role of microRNA-150 in solid tumors. *Oncol Lett* 10: 11-16, 2015.
29. Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K, Ren G, Su T, Pan Y, Feng B, *et al*: miR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. *Biochem Biophys Res Commun* 392: 340-345, 2010.
30. Huang S, Chen Y, Wu W, Ouyang N, Chen J, Li H, Liu X, Su F, Lin L and Yao Y: miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. *PLoS One* 8: e80707, 2013.
31. Okato A, Arai T, Kojima S, Koshizuka K, Osako Y, Idichi T, Kurozumi A, Goto Y, Kato M, Naya Y, *et al*: Dual strands of pre-miR-150 (miR-150-5p and miR-150-3p) act as antitumor miRNAs targeting SPOCK1 in naïve and castration-resistant prostate cancer. *Int J Oncol* 51: 245-256, 2017.
32. Osako Y, Seki N, Koshizuka K, Okato A, Idichi T, Arai T, Omoto I, Sasaki K, Uchikado Y, Kita Y, *et al*: Regulation of SPOCK1 by dual strands of pre-miR-150 inhibit cancer cell migration and invasion in esophageal squamous cell carcinoma. *J Hum Genet* 62: 935-944, 2017.
33. Desgrosellier JS and Cheresch DA: Integrins in cancer: Biological implications and therapeutic opportunities. *Nat Rev Cancer* 10: 9-22, 2010.
34. Gilcrease MZ: Integrin signaling in epithelial cells. *Cancer Lett* 247: 1-25, 2007.
35. Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao Y, Wang XA, Zhang F, Xiang SS, Li HF, *et al*: SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway. *Mol Cancer* 14: 12, 2015.
36. Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ and Kim TY: Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. *Oncogene* 33: 3334-3341, 2014.
37. Miao L, Wang Y, Xia H, Yao C, Cai H and Song Y: SPOCK1 is a novel transforming growth factor- β target gene that regulates lung cancer cell epithelial-mesenchymal transition. *Biochem Biophys Res Commun* 440: 792-797, 2013.
38. Wang YZ, Wu KP, Wu AB, Yang ZC, Li JM, Mo YL, Xu M, Wu B and Yang ZX: MMP-14 overexpression correlates with poor prognosis in non-small cell lung cancer. *Tumour Biol* 35: 9815-9821, 2014.
39. Lu H, Hu L, Yu L, Wang X, Urvalek AM, Li T, Shen C, Mukherjee D, Lahiri SK, Wason MS, *et al*: KLF8 and FAK cooperatively enrich the active MMP14 on the cell surface required for the metastatic progression of breast cancer. *Oncogene* 33: 2909-2917, 2014.
40. Hagemann T, Gunawan B, Schulz M, Füzesi L and Binder C: mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. *Eur J Cancer* 37: 1839-1846, 2001.
41. Gawden-Bone C, Zhou Z, King E, Prescott A, Watts C and Lucocq J: Dendritic cell podosomes are protrusive and invade the extracellular matrix using metalloproteinase MMP-14. *J Cell Sci* 123: 1427-1437, 2010.
42. Gálvez BG, Matías-Román S, Yáñez-Mó M, Sánchez-Madrid F and Arroyo AG: ECM regulates MT1-MMP localization with β 1 or α 5 β 3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. *J Cell Biol* 159: 509-521, 2002.
43. Munshi HG and Stack MS: Reciprocal interactions between adhesion receptor signaling and MMP regulation. *Cancer Metastasis Rev* 25: 45-56, 2006.
44. Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, Huh JW, Lee JH and Kim HR: CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. *Int J Oncol* 41: 211-218, 2012.
45. Zarrabi K, Dufour A, Li J, Kuscus C, Pulkoski-Gross A, Zhi J, Hu Y, Sampson NS, Zucker S and Cao J: Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. *J Biol Chem* 286: 33167-33177, 2011.
46. Hojilla CV, Mohammed FF and Khokha R: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. *Br J Cancer* 89: 1817-1821, 2003.
47. Li Y, Kuscus C, Banach A, Zhang Q, Pulkoski-Gross A, Kim D, Liu J, Roth E, Li E, Shroyer KR, *et al*: miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14. *Cancer Res* 75: 2674-2685, 2015.
48. Zuo QF, Cao LY, Yu T, Gong L, Wang LN, Zhao YL, Xiao B and Zou QM: MicroRNA-22 inhibits tumor growth and metastasis in gastric cancer by directly targeting MMP14 and Snail. *Cell Death Dis* 6: e2000, 2015.
49. Osako Y, Seki N, Kita Y, Yonemori K, Koshizuka K, Kurozumi A, Omoto I, Sasaki K, Uchikado Y, Kurahara H, *et al*: Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. *Int J Oncol* 49: 2255-2264, 2016.
50. Yonemori M, Seki N, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M and Enokida H: Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. *Cancer Sci* 107: 1233-1242, 2016.